专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20050081257A1 Method of producing non-human mammals 审中-公开
标题翻译：生产非人类哺乳动物的方法
公开(公告)号：US20050081257A1
公开(公告)日：2005-04-14
申请号：US10850344
申请日：2004-05-19
申请人： Kevin Eggan , Rudolf Jaenisch
发明人： Kevin Eggan , Rudolf Jaenisch
IPC分类号： A01K67/027 , C12N15/06 , C12N15/873 , C12Q1/68 , C12N5/06
CPC分类号： C12N15/873 , A01K67/027 , A01K2217/05 , A01K2217/075 , C12N2510/00 , C12N2517/02
摘要： A method of producing mutant/targeted non-human mammals, such as mutant mice that does not require production of chimera and permits the introduction of multiple mutations in embryos and, thus, avoids the necessity of breeding to combine all of the desired mutations in a single animal. The method is efficient in producing ES mice.
摘要翻译：一种产生突变体/靶向非人哺乳动物的方法，例如不需要生产嵌合体的突变小鼠，并且允许在胚胎中引入多个突变，并且因此避免育种的必要性以将所有所需的突变组合在单一动物。该方法在产ES小鼠方面是有效的。

22. 发明授权

US06121003A Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use 失效
标题翻译：对磷酸化tau表位特异的单克隆抗体及其用途
公开(公告)号：US06121003A
公开(公告)日：2000-09-19
申请号：US776404
申请日：1997-03-24
申请人： Eugeen Vanmechelen , Andre Van De Voorde
发明人： Eugeen Vanmechelen , Andre Van De Voorde
IPC分类号： C12N15/02 , C07K14/47 , C07K16/18 , C12N5/10 , C12N5/20 , C12N9/12 , C12N15/06 , C12P21/08 , G01N33/577 , G01N33/68 , G01N33/53 , C07K16/00
CPC分类号： C07K16/18 , C07K14/4711 , C12N9/12 , Y10S435/975 , Y10S436/811
摘要： The present invention relates to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which neurofibrillary tangle (NFT) is not a pathological hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention.
摘要翻译： PCT No.PCT / EP95 / 03032 Sec。 371日期1997年3月24日 102（e）1997年3月24日PCT PCT 1995年7月31日PCT公布。公开号WO96 / 04309 日期1996年2月15日本发明涉及一种单克隆抗体，其形成具有特定亚类或形式的磷酸化tau蛋白的磷酸化表位的免疫复合物，而不形成免疫复合物（i）胎儿tau或（ii）活检或尸检患有死亡或患有神经原纤维缠结（NFT）不是病理特征的疾病的患者的衍生脑部材料。本发明还涉及涉及本发明的单克隆抗体的脑疾病的诊断方法。本发明还涉及由本发明的单克隆抗体特异性识别的tau分子的区域。

23. 发明授权

US06056959A CD40 antigen antibody complex 失效
标题翻译： CD40抗原抗体复合物
公开(公告)号：US06056959A
公开(公告)日：2000-05-02
申请号：US463893
申请日：1995-06-05
申请人： Mark de Boer , Leah B Conroy
发明人： Mark de Boer , Leah B Conroy
IPC分类号： C12N15/02 , A61K31/4353 , A61K31/436 , A61K31/573 , A61K38/00 , A61K39/395 , A61K45/00 , A61P1/16 , A61P7/06 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/705 , C07K16/00 , C07K16/28 , C12N5/10 , C12N15/06 , C12N15/09 , C12P21/02 , C12P21/08 , G01N33/53 , G01N33/531 , A61K35/28 , C07K14/435
CPC分类号： C07K16/2878 , A61K39/395 , C07K14/705 , C07K14/70532 , C07K14/70578 , C07K16/2827 , A61K2039/505 , A61K2039/5154 , A61K2039/5156 , A61K38/00 , C07K2317/24 , C07K2317/73 , C07K2317/74 , C07K2319/00 , C07K2319/30 , C12N2799/026
摘要： Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.
摘要翻译：提供了用于预防或治疗患者中抗体介导的死亡酶的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

24. 发明授权

US6033876A Anti-CD30 antibodies preventing proteolytic cleavage and release of membrane-bound CD30 antigen 失效
标题翻译：抗CD30抗体阻止蛋白水解切割和释放膜结合的CD30抗原
公开(公告)号：US6033876A
公开(公告)日：2000-03-07
申请号：US860727
申请日：1997-09-26
申请人： Hilmar Lemke , Hinrich-Peter Hansen
发明人： Hilmar Lemke , Hinrich-Peter Hansen
IPC分类号： C12N15/02 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/30 , C12N5/20 , C12N15/06 , C12N15/13 , C12P21/08 , G01N33/53
CPC分类号： C07K16/3061 , A61K38/00 , C07K2317/24
摘要： An antibody which binds to the CD30 antigen and a) inhibits the release of sCD30 from Hodgkin's disease cells, and b) does not bind to B cell non-Hodgkin's lymphomas or plasma cells. An example of such antibodies are the antibodies secreted from hybridoma cell line DSM ACC 2204. The antibodies may be used for diagnosis, or conjugated to a toxin to produce an immunotoxin.
摘要翻译： PCT No.PCT / EP96 / 00098 Sec。 371日期：1997年9月26日 102（e）1997年9月26日PCT PCT 1996年1月11日PCT公布。公开号WO96 / 22384 日期1996年7月25日一种结合CD30抗原的抗体和a）抑制hodgkin病细胞释放sCD30，b）不结合B细胞非霍奇金淋巴瘤或浆细胞。这种抗体的一个实例是从杂交瘤细胞系DSM ACC 2204分泌的抗体。抗体可用于诊断或与毒素缀合以产生免疫毒素。

25. 发明授权

US5994088A Methods and reagents for preparing and using immunological agents specific for P-glycoprotein 失效
公开(公告)号：US5994088A
公开(公告)日：1999-11-30
申请号：US752447
申请日：1996-11-15
申请人： Eugene Mechetner , Igor B. Roninson
发明人： Eugene Mechetner , Igor B. Roninson
IPC分类号： A61K38/00 , C07K16/28 , C12N15/06 , C12P21/04 , G01N33/50 , G01N33/569 , G01N33/53 , C12N5/20
CPC分类号： G01N33/5094 , C07K16/28 , G01N33/5008 , G01N33/5011 , G01N33/5014 , G01N33/56972 , A61K38/00 , C07K2319/00 , C12N2799/027 , G01N2333/705 , G01N2333/70596
摘要： This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.

26. 发明授权

US5843779A Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies 失效
标题翻译：针对微管相关蛋白tau的单克隆抗体，以及分泌这些抗体的杂交瘤
公开(公告)号：US5843779A
公开(公告)日：1998-12-01
申请号：US244951
申请日：1995-01-19
申请人： Marc Vandermeeren , Marc Mercken , Eugeen Vanmechelen , Andre Van De Voorde
发明人： Marc Vandermeeren , Marc Mercken , Eugeen Vanmechelen , Andre Van De Voorde
IPC分类号： G01N33/53 , A61K39/00 , A61K39/395 , C07K7/06 , C07K14/47 , C07K16/18 , C12N5/00 , C12N5/10 , C12N5/20 , C12N15/02 , C12N15/06 , C12P21/08 , C12R1/91 , G01N33/577 , G01N33/68 , C12N5/06
CPC分类号： C07K16/18 , C07K14/4711
摘要： The invention relates to a monoclonal antibody AT 120 which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.
摘要翻译： PCT No.PCT / EP93 / 03499。 371日期：1994年8月16日 102（e）日期1994年8月16日PCT提交1993年12月10日PCT公布。第WO94 / 13795号公报日期1994年6月23日本发明涉及与属于正常人tau蛋白的抗原的表位以及异常磷酸化的人tau蛋白形成免疫复合物的单克隆抗体AT 120，所述tau蛋白易于从一种脑匀浆，本身与人脑皮层分离。本发明的单克隆抗体可用于检测脑提取物和未浓缩脑脊液中的tau和异常磷酸化tau。

27. 发明授权

US5824639A Modified factor VII anticoagulant proteins 失效
标题翻译：修饰因子VII抗凝血蛋白
公开(公告)号：US5824639A
公开(公告)日：1998-10-20
申请号：US152199
申请日：1993-11-12
申请人： Kathleen L. Berkner
发明人： Kathleen L. Berkner
IPC分类号： C12N15/09 , A61K38/00 , A61K38/43 , A61P7/02 , C07K14/745 , C12N5/10 , C12N9/64 , C12N15/06 , C12N15/57 , C12R1/91 , A61K38/36 , A61K38/48
CPC分类号： C12N9/6437 , C12Y304/21021 , A61K38/00
摘要： Factor VII of the coagulation cascade is modified to act as an anticoagulant. Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.
摘要翻译：将凝血级联的因子VII修饰为抗凝血剂。使用氨基酸修饰产生修饰的因子VII，其具有通常激活野生型因子VII的酶对活化的敏感性的显着降低。修饰的因子VII能够与野生型因子VII和/或VIIa竞争结合组织因子，抑制凝血活性。由于修饰的因子VII特别地用于中断凝血级联，所以修饰因子VII的药物组合物可以代替常规抗凝血剂治疗或与较低剂量的常规抗凝血剂疗法一起施用。

28. 发明授权

US5675063A Immortalized rabbit hybridoma fusion partner 失效
标题翻译：永生化兔杂交瘤融合伴侣
公开(公告)号：US5675063A
公开(公告)日：1997-10-07
申请号：US396383
申请日：1995-02-28
申请人： Katherine L. Knight
发明人： Katherine L. Knight
IPC分类号： A01K67/027 , C07K16/42 , C12N5/16 , C12N15/85 , C12N15/00 , C12N5/12 , C12N5/24 , C12N15/06
CPC分类号： C12N15/8509 , A01K67/0275 , C07K16/4283 , C12N5/163 , A01K2217/05 , A01K2227/107 , A01K2267/01
摘要： Novel methods are provided for producing rabbit fusion partners for the production of specific binding proteins, particularly immunoglobulins. Nuclei of rabbit fertilized ova are microinjected with an oncogene to express specifically in lymphoid cells (i.e., lymphoid specific) and the embryos are then implanted in appropriate hosts. The newborns are maintained to sexual maturity and are either mated with rabbit hosts that developed from embryos that had been microinjected with a different lymphoid-specific oncogene or their fertilized eggs are microinjected with another oncogene specific for lymphoid cells. The immortalized lymphoid cells that develop in these animals may be genetically altered and used as fusion partners to produce rabbit hybridomas for the production of monoclonal antibodies.
摘要翻译：提供了用于产生用于产生特异性结合蛋白质，特别是免疫球蛋白的兔融合伴侣的新方法。兔受精卵的核被癌基因显微注射以在淋巴样细胞中特异性表达（即淋巴特异性），然后将胚胎植入合适的宿主中。新生儿维持性成熟，并且与已经用不同淋巴特异性致癌基因显微注射的胚胎发育的兔子宿主配对，或者它们的受精卵用另一种特异于淋巴细胞的癌基因显微注射。在这些动物中发育的永生化淋巴样细胞可能被遗传改变并用作融合伴侣以产生用于产生单克隆抗体的兔杂交瘤。

29. 发明授权

US5661006A DNA encoding the Canine coronavirus spike protein 失效
标题翻译：编码犬冠状病毒穗蛋白的DNA
公开(公告)号：US5661006A
公开(公告)日：1997-08-26
申请号：US308872
申请日：1994-09-19
申请人： Thomas David Kay Brown , Brian Colin Horsburgh
发明人： Thomas David Kay Brown , Brian Colin Horsburgh
IPC分类号： A61K39/00 , A61K39/215 , A61P31/12 , C07K14/165 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/50 , C12N15/86 , C12N15/863 , C12P21/02 , C12R1/91 , C12R1/92 , C07H21/00 , C12N15/06 , C12N15/63
CPC分类号： C07K14/005 , C12N15/86 , A61K39/00 , C12N2710/24143 , C12N2770/20022
摘要： The invention is related to a nucleic acid sequence &coding a Canine coronavirus (CCV) spike protein. Such a protein can be used for the immunization of dogs against CCV infection. The nucleic acid sequence encoding the CCV spike protein can be applied for the preparation of the spike protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.
摘要翻译：本发明涉及编码犬冠状病毒（CCV）刺突蛋白的核酸序列。这样的蛋白质可以用于狗免疫CCV感染。编码CCV尖峰蛋白的核酸序列可以通过基因工程技术应用于尖峰蛋白的制备，或者可以用于制备载体疫苗。

30. 发明授权

US5635601A Beta-8 integrin subunit antibodies 失效
标题翻译： β-8整合素亚基抗体
公开(公告)号：US5635601A
公开(公告)日：1997-06-03
申请号：US454455
申请日：1995-05-30
申请人： Matthew Moyle , John W. McLean
发明人： Matthew Moyle , John W. McLean
IPC分类号： A61K39/395 , C07K14/00 , C07K14/705 , C07K16/00 , C07K19/00 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12Q1/68 , G01N33/53 , C07K16/28 , C12N15/06 , C12P21/08
CPC分类号： C07K14/70546
摘要： The cDNA encoding a novel beta integrin subunit, called the beta-8 integrin subunit, has been isolated from rabbit and human tissue and sequenced. Provided herein is nucleic acid sequence of the beta-8 integrin subunit useful as a diagnostic and in the recombinant preparation of beta-8 integrin subunit and alpha-beta integrin complexes. The beta-8 integrin subunit is used in the preparation and purification of antibodies thereto, and in diagnostic assays.
摘要翻译：已经从兔和人组织中分离出编码新型β整联蛋白亚基的cDNA，称为β-8整联蛋白亚基，并测序。本文提供了可用作诊断性β-8整联蛋白亚基和α-β整联蛋白复合物的重组制备的β-8整联蛋白亚基的核酸序列。 β-8整联蛋白亚基用于制备和纯化其抗体，并用于诊断测定。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式